Solid Tumor to Register 11.2% CAGR during the Forecast Period, States Future Market Insights

4 minutes, 0 seconds Read

NEWARK, Del: In 2021, the global Oncology-based In-vivo CRO Market was estimated to be worth around US$ 1 billion. With a projected CAGR of 10.9% over the next ten years, the market is expected to be worth nearly US$ 2.9 billion by the end of 2033. By 2033, the absolute dollar opportunity in the Oncology-based In-vivo CRO Market is expected to be US$ 1.8 billion.

Solid tumors account for 90% of adult cancer cases. This increases the need for outsourcing oncology-based research studies so that the end-users can focus on vital aspects to stay competitive in the market.

An increasing number of drugs being developed, new therapeutic modalities, advanced clinical practices, and emerging technologies have been driving the demand for Oncology-based in-vivo CRO. With the rising number of pharmaceutical companies, research and development activities are being outsourced to CRO services due to lower costs and focus on aspects that are more vital. CROs have gained the momentum to offer pharmaceutical organizations their research and development services and eliminate the hurdles that the companies face.

Request Sample @ 

US to Dominate Oncology-Based In-vivo CRO Market throughout the Analysis Period

The US generated the highest revenue in the oncology based in-vivo CRO market in 2022. The market in the US is valued at US$ 1.2 Billion by 2033. The rise in the market can be attributed due to the prevalence of pharmaceutical companies and life science firms that are involved in developing a new drug for the treatment of cancer and receiving grants and funds from government organizations. The absolute dollar opportunity in the oncology-based in-vivo CRO market in the U.S. is estimated at US$ 827.5 Million by 2033.

Competitive Landscape

Companies involved in the Oncology-based In-vivo CRO Market are largely aiming at setting up clinical facilities, winning orders, and aiming at developing drugs for the treatment of cancer. The key companies operating in the Oncology-based In-vivo CRO Market include The Jackson Laboratory, EVOTEC, WuXi AppTec, Toxicon Inc., Crown Bioscience, Taconic Biosciences, Eurofins Scientific, ICON Plc, Charles River Laboratory, and Covance.

Request Customization @ 

Some of the recent developments by key providers of Oncology-based in-vivo CRO are as follows:

  • In July 2022, researchers from Jackson Laboratory (JAX) were successful in demonstrating, why patients with BRCA mutations are able to respond properly and develop resistance from platinum-based therapy than BRCA1 promoter methylation. The team used patient data, patient-derived xenograft (PDX) mouse models, and engineered cancer cell lines.  They also developed an algorithm for TNBC and ovarian cancer that shows the potential response to chemotherapy and prevents patients from overtreatment.
  • In May 2022, The Jackson Laboratory team deployed machine learning to capture precise insights about cancer patients and interpret tumor images faster and more accurately providing the possibility of more focused treatment without the need for additional testing.
  • In October 2021, Charles River Laboratories in Japan was acquired by Jackson Laboratory, which is now known as Jackson Laboratory Japan. JAX provides access to animal models, resources, and scientific support to the new company and will assist researchers to make scientific advancements and breakthroughs in drug development.
  • In October 2021, Crown Bioscience launched the 3D ex Vivo Patient Tissue Platform. The platform uses the tumor tissue of the patient, which is extracted by biopsies, surgical resections, and ascites or from the samples of pleural effusion and is processed to preserve the tumor microenvironment.

Buy Now/Purchase @ 

Key Segments Covered in Oncology-based in-vivo CRO Industry Survey

By Indication:

  • Blood Cancer
    • Syngeneic Model
    • Patient Derived Xenograft (PDX)
    • Xenograft
  • Solid Tumors
    • Syngeneic Model
    • Patient Derived Xenograft (PDX)
    • Xenograft
  • Other Indications
    • Syngeneic Model
    • Patient Derived Xenograft (PDX)
    • Xenograft

Table of Content

1. Executive Summary | Oncology-Based In-vivo CRO Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

Complete TOC with Report Preview: 

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S., and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

LinkedInTwitterBlogs | YouTube

For Sales Enquiries:

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *